Breaking News Instant updates and real-time market news.

SGEN

Seattle Genetics

$51.65

-0.04 (-0.08%)

08:03
04/12/18
04/12
08:03
04/12/18
08:03

Seattle Genetics highlights ADC technologies, immuno-oncology program at AACR

Seattle Genetics announced data highlights from nine presentations showcasing the company's proprietary antibody-drug conjugate platform technologies as well as its emerging immuno-oncology pipeline. Data include preclinical and clinical advances with ADCETRIS, ladiratuzumab vedotin, SGN-CD48A and SGN-2FF. Additionally, Seattle Genetics will present the first preclinical data describing the novel empowered antibody SEA-BCMA. These data will be presented at the American Association for Cancer Research Annual Meeting 2018. Abstracts include the following: An oral presentation and poster presentation on Sunday and Monday, April 15 and 16, 2018, respectively, will showcase preclinical data evaluating proprietary NAMPT inhibitors and auristatins as ADC payloads. The data show NAMPT inhibitors have a unique mechanism of action and encouraging therapeutic window. Preclinical data also describe the development of novel auristatin payloads with potential application across multiple tumor types. An innovative approach to masking antibodies for tumor specific activation will be featured in a poster presentation on Sunday, April 15, 2018. Preclinical data demonstrate that coiled-coil masked antibodies and ADCs show improved tolerability and equivalent antitumor activity compared to unmasked counterparts. The data suggest this technology may be applied to a range of antibodies or ADCs and could enable their development against previously inaccessible cancer targets. The novel preclinical program SEA-BCMA will be highlighted in a poster presentation on Tuesday, April 17, 2018. The cell surface protein BCMA is expressed on cells of several cancer types, including multiple myeloma and other B cell malignancies. SEA-BCMA is an antibody empowered using Seattle Genetics' proprietary Sugar Engineered Antibody technology designed to enhance antibody effector functions. The preclinical data support initiation of a phase 1 trial for multiple myeloma, which is planned for 2018. Clinical biomarker data from a phase 1 trial evaluating the novel immuno-oncology agent SGN-2FF in patients with advanced solid tumors will be shown in a poster presentation on Wednesday, April 18, 2018. The preliminary data demonstrate the biological effects of SGN-2FF and support further development of this novel immuno-oncology agent. Three poster presentations on Monday and Wednesday, April 16 and 18, 2018 will highlight preclinical data evaluating the ability of ADCETRIS, ladiratuzumab vedotin and SGN-CD48A, each of which are auristatin-based ADCs, to elicit additional mechanisms of action, including immunogenic cell death. These data support clinical evaluation in combination with checkpoint inhibitors. ADCETRIS and ladiratuzumab vedotin are being evaluated in combination with checkpoint inhibitors in multiple ongoing clinical trials.

  • 26

    Apr

  • 01

    May

  • 12

    Jun

SGEN Seattle Genetics
$51.65

-0.04 (-0.08%)

02/07/18
RHCO
02/07/18
NO CHANGE
Target $60
RHCO
Hold
Seattle Genetics price target raised to $60 from $52 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Seattle Genetics to $60 after a Q4 earnings beat on slightly higher than expected Adcetris sales and lower R&D expenses. Suneja keeps his Hold rating on Seattle Genetics, warning that the "full E-1 data at ASH suggest the market potential for Adcetris in this indication (1L cHL) could be rather limited".
02/14/18
JPMS
02/14/18
UPGRADE
Target $66
JPMS
Overweight
Seattle Genetics upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov upgraded Seattle Genetics to Overweight and raised his price target for the shares to $66 from $60. The analyst sees a "compelling opportunity" for the company from a solid launch for Adcetris in frontline Hodgkin Lymphoma as well as another Phase 3 data set for mature T-cell lymphoma. The analyst is encouraged by the "significant steps" Seattle Genetics has taken to broaden its pipeline beyond Adcetris. He likes the stock's risk/reward at current share levels.
03/20/18
LEHM
03/20/18
INITIATION
Target $74
LEHM
Overweight
Seattle Genetics reinstated with an Overweight at Barclays
Barclays analyst Geoff Meacham reinstated Seattle Genetics with an Overweight rating and $74 price target. The near-term investment case will be driven by the expansion of Adcetris into the front-line Hodgkin lymphoma setting, but the just completed Cascadian acquisition "adds a new dimension with expansion into the solid tumor arena," Meacham tells investors in a research note. He believes the deal "provides significant optionality over the intermediate/long term."
03/21/18
CANT
03/21/18
NO CHANGE
Target $50
CANT
Neutral
Seattle Genetics approval already reflected in expectations, says Cantor
The Adcetris label expansion approved yesterday for frontline Hodgkin lymphoma was expected, Cantor Fitzgerald analyst Mara Goldstein tells investors in a research note. The analyst continues to believe that upside from additional indications is already built into Adcetris' growth rate and the stock's current valuation. She maintains a Neutral rating on Seattle Genetics with a $50 price target.

TODAY'S FREE FLY STORIES

AA

Alcoa

$59.78

-0.47 (-0.78%)

, AAL

American Airlines

$46.58

-0.3 (-0.64%)

16:02
04/20/18
04/20
16:02
04/20/18
16:02
Periodicals
Breaking Periodicals news story on Alcoa, American Airlines, Alaska Air, Boeing, Delta Air Lines, General Electric, Southwest, United Continental, JetBlue »

FAA to prepare emergency…

AA

Alcoa

$59.78

-0.47 (-0.78%)

AAL

American Airlines

$46.58

-0.3 (-0.64%)

ALK

Alaska Air

$65.41

-0.14 (-0.21%)

BA

Boeing

$337.30

-3.25 (-0.95%)

DAL

Delta Air Lines

$55.33

0.27 (0.49%)

GE

General Electric

$14.65

0.655 (4.68%)

LUV

Southwest

$54.64

-0.14 (-0.26%)

UAL

United Continental

$71.73

1.485 (2.11%)

JBLU

JetBlue

$19.83

0.17 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 09

    May

  • 10

    May

  • 29

    May

  • 30

    May

  • 26

    Jun

  • 29

    Jun

PSX

Phillips 66

$110.85

0.23 (0.21%)

15:55
04/20/18
04/20
15:55
04/20/18
15:55
Options
Phillips 66 put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

ULTI

Ultimate Software

$244.01

-4.76 (-1.91%)

15:51
04/20/18
04/20
15:51
04/20/18
15:51
Hot Stocks
Ultimate Software announces SMS Equipment to use its reporting product »

Ultimate Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 12

    Jun

C

Citi

$69.85

-0.43 (-0.61%)

, USB

U.S. Bancorp

$50.24

-0.45 (-0.89%)

15:49
04/20/18
04/20
15:49
04/20/18
15:49
Periodicals
Big U.S. banks race to launch mortgage apps as home lending slows, Reuters says »

Large U.S. banks are…

C

Citi

$69.85

-0.43 (-0.61%)

USB

U.S. Bancorp

$50.24

-0.45 (-0.89%)

JPM

JPMorgan

$111.07

-0.66 (-0.59%)

BAC

Bank of America

$30.19

-0.015 (-0.05%)

GS

Goldman Sachs

$251.52

-2.67 (-1.05%)

WFC

Wells Fargo

$52.49

0.94 (1.82%)

MS

Morgan Stanley

$54.11

-0.58 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 02

    May

  • 15

    May

  • 16

    May

  • 23

    May

  • 30

    May

  • 06

    Jun

  • 13

    Jul

  • 12

    Oct

T

AT&T

$34.67

-0.15 (-0.43%)

, VZ

Verizon

$48.01

-0.43 (-0.89%)

15:46
04/20/18
04/20
15:46
04/20/18
15:46
Periodicals
U.S. investigating wireless collusion claim against AT&T, Verizon, NY Times says »

The U.S. Department of…

T

AT&T

$34.67

-0.15 (-0.43%)

VZ

Verizon

$48.01

-0.43 (-0.89%)

S

Sprint

$6.00

0.045 (0.76%)

TMUS

T-Mobile

$63.28

0.02 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 09

    May

HPE

HP Enterprise

$17.23

-0.19 (-1.09%)

15:45
04/20/18
04/20
15:45
04/20/18
15:45
Options
Hewlett Packard Enterprise call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 11

    Jun

T

AT&T

$34.64

-0.18 (-0.52%)

, VZ

Verizon

$47.99

-0.45 (-0.93%)

15:42
04/20/18
04/20
15:42
04/20/18
15:42
Periodicals
Breaking Periodicals news story on AT&T, Verizon, Sprint, T-Mobile »

U.S. investigating…

T

AT&T

$34.64

-0.18 (-0.52%)

VZ

Verizon

$47.99

-0.45 (-0.93%)

S

Sprint

$6.00

0.045 (0.76%)

TMUS

T-Mobile

$63.27

0.01 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 09

    May

ALXN

Alexion

$106.59

-5.15 (-4.61%)

15:36
04/20/18
04/20
15:36
04/20/18
15:36
Hot Stocks
Alexion says no licence of Soliris was requested or granted in Brazil »

Recent media reports have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

SYNT

Syntel

$28.04

0.19 (0.68%)

15:35
04/20/18
04/20
15:35
04/20/18
15:35
Recommendations
Syntel analyst commentary  »

Syntel's rest of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

TRUP

Trupanion

$27.51

-1.42 (-4.91%)

15:35
04/20/18
04/20
15:35
04/20/18
15:35
Periodicals
Trupanion cost saving sharing may violate state laws, Capitol Forum says »

Insurance experts and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 10

    May

BURL

Burlington Stores

$132.82

-3.36 (-2.47%)

15:30
04/20/18
04/20
15:30
04/20/18
15:30
Options
Bullish option play in Burlington Stores as shares slump »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$35.35

-0.25 (-0.70%)

, FOXA

21st Century Fox

$36.69

-0.51 (-1.37%)

15:29
04/20/18
04/20
15:29
04/20/18
15:29
Hot Stocks
Box Office Battle: 'A Quiet Place' expected to creep back into top spot »

Expected to return to the…

VIA

Viacom

$35.35

-0.25 (-0.70%)

FOXA

21st Century Fox

$36.69

-0.51 (-1.37%)

LGF.B

Lionsgate

$23.89

-0.55 (-2.25%)

VIAB

Viacom

$30.77

0.02 (0.07%)

CMCSA

Comcast

$33.14

-0.35 (-1.05%)

CMCSK

Comcast

LGF.A

Lionsgate

$25.72

-0.48 (-1.83%)

TWX

Time Warner

$95.98

-0.59 (-0.61%)

DIS

Disney

$100.01

-0.87 (-0.86%)

SNE

Sony

$49.70

-0.03 (-0.06%)

FOX

21st Century Fox

$36.12

-0.55 (-1.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 08

    May

  • 09

    May

  • 09

    May

ALXN

Alexion

$106.37

-5.37 (-4.81%)

15:28
04/20/18
04/20
15:28
04/20/18
15:28
Recommendations
Alexion analyst commentary  »

Alexion shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

ANF

Abercrombie & Fitch

$26.36

-1.08 (-3.94%)

15:25
04/20/18
04/20
15:25
04/20/18
15:25
Options
Abercrombie & Fitch call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 12

    Jun

MEOH

Methanex

$66.80

-0.65 (-0.96%)

15:25
04/20/18
04/20
15:25
04/20/18
15:25
Hot Stocks
Breaking Hot Stocks news story on Methanex »

M&G Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$66.01

-1.14 (-1.70%)

, XLP

Consumer Staples Sector SPDR

$50.43

-0.91 (-1.77%)

15:21
04/20/18
04/20
15:21
04/20/18
15:21
Technical Analysis
Technical Take: SPDR S&P 500 ETF falls to session lows heading to the close »

The SPDR S&P 500 ETF…

XLK

Technology Select Sector SPDR

$66.01

-1.14 (-1.70%)

XLP

Consumer Staples Sector SPDR

$50.43

-0.91 (-1.77%)

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$265.88

-2.96 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
04/20/18
04/20
15:17
04/20/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OPBK

OP Bancorp

15:16
04/20/18
04/20
15:16
04/20/18
15:16
Hot Stocks
Breaking Hot Stocks news story on OP Bancorp  »

SCW Capital reports 5.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
04/20/18
04/20
15:16
04/20/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$7.80

1.16 (17.47%)

15:10
04/20/18
04/20
15:10
04/20/18
15:10
Options
Bullish option play in Ericsson as shares surge to 52-week highs »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$21.99

0.46 (2.14%)

15:08
04/20/18
04/20
15:08
04/20/18
15:08
Hot Stocks
Value Line raises quarterly dividend 5.56% to 19c per common share »

Value Line announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAWS

Lawson Products

$24.60

-0.75 (-2.96%)

15:03
04/20/18
04/20
15:03
04/20/18
15:03
Recommendations
Lawson Products analyst commentary  »

Barrington still positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

SMH

Market Vectors Semiconductor

$98.95

-1.21 (-1.21%)

15:00
04/20/18
04/20
15:00
04/20/18
15:00
Options
VanEck Vectors Semi options volume is 3X daily average as shares extend losses »

VanEck Vectors Semi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
04/20/18
04/20
15:00
04/20/18
15:00
General news
Fed's Kashkari is surprised the 10-year rate hasn't risen more »

Fed's Kashkari is…

LLY

Eli Lilly

$79.11

-0.62 (-0.78%)

14:53
04/20/18
04/20
14:53
04/20/18
14:53
Hot Stocks
Eli Lilly says Phase 3 RANGE study didn't reach statistical significance for OS »

Eli Lilly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 07

    May

  • 21

    May

  • 07

    Jun

  • 07

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.